Meeting
2017 Genitourinary Cancers Symposium
Meta-analysis of disease free survival (DFS) as a surrogate for overall survival (OS) in localized renal cell carcinoma (RCC).
Authors
Lauren Christine Harshman
Dana-Farber Cancer Institute, Boston, MA
Lauren Christine Harshman , Wanling Xie , Raphael Brandao Moreira , Ruiz Gustavo , Christopher Sweeney , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 459)
DOI
10.1200/JCO.2017.35.6_suppl.459
Abstract #
459
Poster Bd #
D22
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).
First Author: Daniel Vargas Almeida
Poster
2018 Genitourinary Cancers Symposium
Adjuvant antiangiogenic agents in post-nephrectomy renal cell carcinoma (RCC): A systematic review and meta-analysis.
First Author: Mohamad Bassam Sonbol
Poster
2024 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
First Author: Viktor Grünwald
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
First Author: Kevin Yan